Compare SMG & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMG | ARQT |
|---|---|---|
| Founded | 1868 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.6B |
| IPO Year | 2012 | 2020 |
| Metric | SMG | ARQT |
|---|---|---|
| Price | $55.80 | $20.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $73.00 | $34.00 |
| AVG Volume (30 Days) | 920.2K | ★ 2.1M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | ★ 504.92 | 88.79 |
| EPS | ★ 1.93 | N/A |
| Revenue | ★ $3,016,500,000.00 | $376,072,000.00 |
| Revenue This Year | N/A | $34.85 |
| Revenue Next Year | $2.63 | $29.39 |
| P/E Ratio | $30.43 | ★ N/A |
| Revenue Growth | 6.17 | ★ 91.34 |
| 52 Week Low | $52.00 | $12.72 |
| 52 Week High | $72.35 | $31.77 |
| Indicator | SMG | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 37.31 | 42.49 |
| Support Level | $52.91 | $19.45 |
| Resistance Level | $58.68 | $21.84 |
| Average True Range (ATR) | 2.33 | 0.93 |
| MACD | -0.02 | 0.11 |
| Stochastic Oscillator | 26.27 | 44.53 |
Scotts Miracle-Gro is the largest purveyor of home lawn and gardening products in the US. The company sells a broad range of lawncare products, including grass seed, fertilizer, and lawn-related weed, animal, and disease control. US consumer typically generates the vast majority of companywide revenue and profits. Its lawncare and gardening products are well-recognized brands in the US, including Scotts, Miracle-Gro, Roundup, Ortho, and Tomcat. Over half of revenue typically comes from Home Depot and Lowe's, as Scotts' products are featured at both home improvement retailers.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.